Compare YJ & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YJ | CYCN |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 7.6M |
| IPO Year | 2019 | N/A |
| Metric | YJ | CYCN |
|---|---|---|
| Price | $1.50 | $1.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.0K | ★ 1.1M |
| Earning Date | 11-25-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $47,760,127.00 | $2,855,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1371.65 |
| 52 Week Low | $1.37 | $1.28 |
| 52 Week High | $2.67 | $9.47 |
| Indicator | YJ | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 33.44 | 51.46 |
| Support Level | $1.51 | $1.48 |
| Resistance Level | $1.65 | $1.60 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 22.25 | 93.75 |
Yunji Inc is a social e-commerce platform in China that offers a membership-based model that leverages the power of social interaction. The company provides a host of selected commodities such as beauty and personal care, mobile phones and digital products, baby and maternal products, toys, fruits, and other fresh products. It has expanded to operate its business, including the marketplace, on a diverse range of sales channels and other platforms. Geographically, the firm operates in the PRC.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.